High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
about
Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms.Imaging outcome measures for progressive multiple sclerosis trialsHow to pursue EPO in MS.Progressive multiple sclerosis, cognitive function, and quality of life.Leukemia inhibitory factor inhibits erythropoietin-induced myelin gene expression in oligodendrocytes
P2860
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@en
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@nl
type
label
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@en
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@nl
prefLabel
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@en
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@nl
P2093
P2860
P50
P921
P356
P1476
High-dose erythropoietin in pa ...... ebo-controlled, phase 2 trial.
@en
P2093
Bjarne Laursen
Camilla Gøbel Madsen
Ellen Garde
Jeppe Romme Christensen
Karen Schreiber
Lars Börnsen
Melinda Magyari
Pernille Iversen
Rikke Ratzer
P2860
P304
P356
10.1177/1352458516661048
P577
2016-08-01T00:00:00Z